Literature DB >> 33552477

Nonalcoholic Steatohepatitis, Sarcopenia, and Liver Transplantation.

Rahima A Bhanji1, Yedidya Saiman2, Kymberly D Watt3.   

Abstract

Watch a video presentation of this article Watch an interview with the author.
© 2021 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2021        PMID： 33552477      PMCID： PMC7849304          DOI： 10.1002/cld.1000

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  14 in total

Review 1.  Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.

Authors:  Rahima A Bhanji; Praveena Narayanan; Alina M Allen; Harmeet Malhi; Kymberly D Watt
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

2.  Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.

Authors:  Ho Cheol Hong; Soon Young Hwang; Hae Yoon Choi; Hye Jin Yoo; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Dong Seop Choi; Kyung Mook Choi
Journal:  Hepatology       Date:  2014-03-24       Impact factor: 17.425

3.  The evolution and impact of sarcopenia pre- and post-liver transplantation.

Authors:  Rahima A Bhanji; Naoki Takahashi; Michael R Moynagh; Praveena Narayanan; Mounika Angirekula; Kristin C Mara; Ross A Dierkhising; Kymberly D Watt
Journal:  Aliment Pharmacol Ther       Date:  2019-02-03       Impact factor: 8.171

Review 4.  A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity.

Authors:  Eileen M Weinheimer; Laura P Sands; Wayne W Campbell
Journal:  Nutr Rev       Date:  2010-07       Impact factor: 7.110

Review 5.  Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.

Authors:  Chalermrat Bunchorntavakul; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-11-08       Impact factor: 8.171

6.  Handgrip Strength Adds More Prognostic Value to the Model for End-Stage Liver Disease Score Than Imaging-Based Measures of Muscle Mass in Men With Cirrhosis.

Authors:  Marie Sinclair; Brooke Chapman; Rudolf Hoermann; Peter W Angus; Adam Testro; Thomas Scodellaro; Paul J Gow
Journal:  Liver Transpl       Date:  2019-08-18       Impact factor: 5.799

7.  A multicenter study to define sarcopenia in patients with end-stage liver disease.

Authors:  Elizabeth J Carey; Jennifer C Lai; Connie W Wang; Srinivasan Dasarathy; Iryna Lobach; Aldo J Montano-Loza; Michael A Dunn
Journal:  Liver Transpl       Date:  2017-05       Impact factor: 5.799

8.  Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease.

Authors:  Da Gan; Lu Wang; Menghan Jia; Yuan Ru; Yiyun Ma; Weifang Zheng; Xueyin Zhao; Fei Yang; Tianru Wang; Yun Mu; Shankuan Zhu
Journal:  Clin Nutr       Date:  2019-04-25       Impact factor: 7.324

9.  Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).

Authors:  Yong-ho Lee; Seung Up Kim; Kijun Song; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Byung-Wan Lee; Eun Seok Kang; Bong-Soo Cha; Kwang-Hyub Han
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

10.  Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease.

Authors:  Rahima A Bhanji; Praveena Narayanan; Michael R Moynagh; Naoki Takahashi; Mounika Angirekula; Cassie C Kennedy; Kristin C Mara; Ross A Dierkhising; Kymberly D Watt
Journal:  Liver Transpl       Date:  2019-01       Impact factor: 5.799
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.